ALX Oncology Holdings (NAS:ALXO) Capex-to-Operating-Income

: 0.00 (As of Dec. 2022)

View and export this data going back to 2020. Start your Free Trial

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

ALX Oncology Holdings's Capital Expenditure for the three months ended in Dec. 2022 was $-0.39 Mil. Its Operating Income for the three months ended in Dec. 2022 was $-32.22 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.

ALX Oncology Holdings Capex-to-Operating-Income Historical Data

The historical data trend for ALX Oncology Holdings's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ALX Oncology Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Capex-to-Operating-Income

ALX Oncology Holdings Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Capex-to-Operating-Income													-	-	-	-	-

Competitive Comparison

For the Biotechnology subindustry, ALX Oncology Holdings's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

ALX Oncology Holdings Capex-to-Operating-Income Distribution

For the Biotechnology industry and Healthcare sector, ALX Oncology Holdings's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where ALX Oncology Holdings's Capex-to-Operating-Income falls in comparison to its industry or sector. The grey bar indicates the Capex-to-Operating-Income's extreme value range as defined by GuruFocus.

ALX Oncology Holdings Capex-to-Operating-Income Calculation

ALX Oncology Holdings's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2022 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-1.427)	/	-127.436
	=	N/A

ALX Oncology Holdings's Capex-to-Operating-Income for the quarter that ended in Dec. 2022 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-0.389)	/	-32.219
	=	N/A

ALX Oncology Holdings (NAS:ALXO) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

ALX Oncology Holdings Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of ALX Oncology Holdings's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

ALX Oncology Holdings (NAS:ALXO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ALX Oncology Holdings Inc (NAS:ALXO) » Definitions » Capex-to-Operating-Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

323 Allerton Avenue, South San Francisco, CA, USA, 94080

Website

https://www.alxoncology.com

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Executives

J. Scott Garland	director	210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Itziar Canamasas	director	C/O ALX ONCOLOGY HOLDINGS INC, 323 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
Shelly Pinto	officer: VP, Finance and CAO	866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Vivo Opportunity Fund, L.p.	10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
Vivo Opportunity, Llc	10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
Michael A Carusi	10 percent owner	1000 WINTER STREET, SUITE 3700, WALTHAM MA 02451
Venbio Global Strategic Gp Ii, Ltd.	10 percent owner, other: See Remarks	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Plain Henry A Jr	10 percent owner	125 CONSTITUTION DRIVE, MENLO PARK CA 94025-1118
Lightstone Ventures, L.p.	10 percent owner	500 BOYLSTON STREET, SUITE 1380, BOSTON MA 02116
Lightstone Ventures (a), L.p.	10 percent owner	500 BOYLSTON STREET, SUITE 1380, BOSTON MA 02116
Lsv Associates, Llc	10 percent owner	2884 SAND HILL ROAD, SUITE 121, MENLO PARK CA 94025
Jason Lettmann	director, 10 percent owner	C/O RA PHARMACEUTICALS, INC., 87 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Lightstone Ventures Ii, L.p.	10 percent owner	500 BOYLSTON STREET, SUITE 1380, BOSTON MA 02116
Lightstone Ventures Ii (a), L.p.	10 percent owner	500 BOYLSTON STREET, SUITE 1380, BOSTON MA 02116
Jaume Pons	director, officer: President and CEO	C/O ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010